Gold and silver nanoparticles conjugated with heparin-derivative possess anti-angiogenesis properties
Loading...
ORCID
https://orcid.org/0000-0003-2219-5833
Other Contributors
Issue Date
Type
Article
Language
ENG
Degree
Alternative Title
Abstract
Silver and gold nanoparticles display unique physical and biological properties that have been extensively studied for biological and medical applications. Typically, gold and silver nanoparticles are prepared by chemical reductants that utilize excess toxic reactants, which need to be removed for biological purposes. We utilized a clean method involving a single synthetic step to prepare metal nanoparticles for evaluating potential effects on angiogenesis modulation. These nanoparticles were prepared by reducing silver nitrate and gold chloride with diaminopyridinyl (DAP)-derivatized heparin (HP) polysaccharides. Both gold and silver nanoparticles reduced with DAPHP exhibited effective inhibition of basic fibroblast growth factor (FGF-2)-induced angiogenesis, with an enhanced anti-angiogenesis efficacy with the conjugation to DAPHP (P<0.01) as compared to glucose conjugation. These results suggest that DAPHP-reduced silver nanoparticles and gold nanoparticles have potential in pathological angiogenesis accelerated disorders such as cancer and inflammatory diseases.
Description
Nanotechnology, 20, 455104
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Full Citation
Gold and silver nanoparticles conjugated with heparin-derivative possess anti-angiogenesis properties, M. M. Kemp, A. Kumar, S. Mousa, E. Dyskin, M. Yalcin, P. Ajayan, R. J. Linhardt, S.A. Mousa, Nanotechnology, 20, 455104, 2009.
Publisher
Terms of Use
Journal
Volume
Issue
PubMed ID
DOI
ISSN
13616528
9574484
9574484
